PAI-1 Polymorphism 4G/5G PAI4G5G

Synonyms

Allscripts (AEHR) Order Name

Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G

Sunrise Clinical Manager (SCM) Order Name

Not Orderable

Clinical Info

Plasma plasminogen activator inhibitor, PAI-1 is a major inhibitor of fibrinolysis. The 4G variant (AF386492.2:g.837del) in the PAI-1 (Serpine 1) gene promoter region is associated with an increase in the level of PAI-1 in plasma. Increased levels of PAI-1 in plasma may increase the risk for arterial and venous thrombosis, myocardial infarction, and progression of atherosclerosis and also recurrent spontaneous abortion.

Specimen Type

Blood

Container

Lavender Top Tube

Collection Instructions

Container/Tube: Lavender top EDTA tube
Specimen:  5 mL EDTA Whole Blood  (3mL min)
Transport Temperature:  Room Temperature 
Stability:    Room temperature: 8 days
                    Refrigerated: 8 days
                    Frozen: Unacceptable
 
Alternative Specimen(s)
Whole blood collected in: sodium heparin (green-top), lithium heparin (green-top), or acid citrate dextrose ACD (yellow-top) tube

Transport Instructions

Room Temperature

Specimen Stability

Room temperature: 8 days
                    Refrigerated: 8 days
                    Frozen: Unacceptable
 
Alternative Specimen(s)
Whole blood collected in: sodium heparin (green-top), lithium heparin (green-top), or acid citrate d

Methodology

Polymerase Chain Reaction (PCR) and Detection

Days Performed

Performing Laboratory

Quest Diagnostics' Nichols Institute, Inc. - Chantilly

CPT

81400
 
LOINC Code: 52757-2
 
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the C

PDM

5914736

Result Interpretation

Interpretive Report
 
TAT: 8- 12 Days

Forms